NCT05828303 2025-04-01A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid TumorsTurning Point Therapeutics, Inc.Phase 1 Withdrawn